NLRP3
NLRP3 (NLR Family Pyrin Domain Containing 3) is a cytosolic pattern-recognition receptor that functions as the sensor component of the NLRP3 inflammasome, enabling innate immune cells to detect microbial motifs, endogenous danger signals, and environmental irritants[1]. Upon activation, NLRP3 oligomerizes and recruits the adaptor ASC and pro-caspase-1, leading to inflammasome assembly, caspase-1 activation, and subsequent maturation of the pro-inflammatory cytokines IL-1β and IL-18 as well as gasdermin D-mediated pyroptosis[1][2]. Mechanistically, canonical NLRP3 activation requires a priming step that enhances NLRP3 and pro-inflammatory cytokine expression, followed by an activation step triggered by diverse stimuli including extracellular ATP, microbial toxins, silica particles, and monosodium urate crystals[2]. Through these signaling processes, NLRP3 regulates inflammation, host defense, and immune homeostasis, while excessive activation promotes pathological inflammatory responses[1][3]. Dysregulated NLRP3 inflammasome activity has been implicated in autoinflammatory syndromes, gout, cardiovascular disease, neurodegenerative disorders, inflammatory bowel disease, and other inflammation-associated conditions[1][3][4]. Compared with other inflammasome-forming NOD-like receptors such as NLRP1 and NLRC4, NLRP3 is distinguished by its ability to respond to an exceptionally broad spectrum of pathogen-associated and danger-associated signals rather than a limited set of ligands[1][4]. For experimental applications, selective NLRP3 inhibitors such as MCC950 suppress inflammasome assembly by targeting the NACHT domain and are widely used to investigate NLRP3-dependent inflammatory mechanisms in preclinical disease models[4].
References:
- [1]. Swanson KV, et al. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019 Aug;19(8):477-489. [Content Brief]
- [2]. Shin HJ, et al. Molecular mechanisms of NLRP3 inflammasome activation. Exp Mol Med. 2026 Mar;58(3):650-663. [Content Brief]
- [3]. Chen Y, et al. The NLRP3 inflammasome: contributions to inflammation-related diseases. Cell Mol Biol Lett. 2023 Jun 27;28(1):51. [Content Brief]
-
NLRP3 Related Products (235)
Related Products (235)
-
Recombinant Proteins (1)
-
Antibodies (1)
-
CAII-IN-11
0 ImagesCat. No.: HY-180916CAII-IN-11 (Compound A1) is a dual-target compound that contains a hCA II inhibitor (IC₅₀ = 2 nM) portion and a NO donor portion. CAII-IN-11 also has inhibitory activity against hCA IX, hCA XII, and hCA I, with IC50 values of 6, 3, and 152 nM respectively. CAII-IN-11 significantly increases the intracellular cGMP level in human trabecular meshwork cells. CAII-IN-11 reduces the apoptosis of retinal ganglion cells by reducing oxidative stress (ROS levels), inhibiting astrocytes and the NLRP3 inflammasome activation. CAII-IN-11 has hypotensive activity in rabbit models and can be used for the study of glaucoma.
-
NLRP3-IN-88
0 ImagesCat. No.: HY-182102CAS No.: 2557349-73-0NLRP3-IN-88 (Compound 1) is an NLRP3 inhibitor. NLRP3-IN-88 inhibits IL-1β. NLRP3-IN-88 can be used in research on intestinal diseases and inflammatory diseases.
-
NLRP3-IN-38
0 ImagesCat. No.: HY-163497CAS No.: 3033054-46-2NLRP3-IN-38 (Compound 18) is an inhibitor for NOD-like receptor protein 3 (NLRP3), that inhibits NLRP3 inflammasome activation with an EC50 of 23 nM.
-
NLRP3-IN-82
0 ImagesCat. No.: HY-175464CAS No.: 3091347-92-8NLRP3-IN-82 (Compound 2b) is a NLRP3IC50< 5 nM). NLRP3-IN-82 can be used for neurological diseases like Alzheimer's disease, inflammatory diseases like inflammatory bowel disease and metabolic disorders like obesity research.
-
NLRP3-IN-14
0 ImagesCat. No.: HY-149121CAS No.: 2767369-80-0NLRP3-IN-14 is a potent and selective NLRP3 inflammasome inhibitor (KD: 5.87 μM). NLRP3-IN-14 inhibits IL-1β release with an IC50 of 0.131 μM. NLRP3-IN-14 can be used for the research of inflammation.
-
NLRP3-IN-32
0 ImagesCat. No.: HY-161329NLRP3-IN-32 (compound 7a), a 3, 4-dihydronaphthalene-1(2H)-one derivative, is a potential NLRP3 inflammatory vesicles inhibitor. NLRP3-IN-32 can block the assembly and activation of NLRP3 inflammasome by down-regulating the expression of NLPR3 and apoptosis-associated speck-like protein containing a CARD (ASC), and inhibiting the production of reactive oxygen species (ROS) and other inflammatory mediators. NLRP3-IN-32 inhibits the phosphorylation of IκBα and NF-κB/p65 and the nuclear translocation of p65, thereby inhibiting NF-κB signaling.
-
Drofenine
0 ImagesDrofenine (Cycloadiphene; Hexahydroadiphenine) is an brain-penetrant antispasmodic agent. Drofenine is a Kv2.1 channel inhibitor with human IC50 of 9.53 μM. Drofenine is a butyrylcholinesterase (BChE) inhibitor with Ki of 0.003 mM, and is a TRPV3 activator. Drofenine blocks Kv2.1-dependent potassium efflux, inhibits Kv2.1/JNK/NF-κB and IkBa/NF-kB signaling, suppresses Kv2.1 mRNA/protein expression. Drofenine suppresses oligomeric Aβ-induced microglial NLRP3 inflammasome activation and neuronal Tau hyperphosphorylation, improves cognitive impairment, promotes neurite outgrowth. Drofenine induces calcium influx in keratinocytes and exert cytotoxicity against keratinocytes. Drofenine ameliorates diabetic peripheral neuropathy -like pathology. Drofenine can be used for the researches of Alzheimer's disease, diabetic peripheral neuropathy and smooth muscle spasm.
-
ABT-546 hydrochloride
0 ImagesCat. No.: HY-19309CAS No.: 223756-43-2Synonyms: A-216546 hydrochlorideABT-546 (A-216546) hydrochloride is an orally active ETA receptor antagonist, with Ki values of 0.46 nM and 13000 nM for human ETA and ETB receptors, respectively, and exhibits >25000-fold selectivity over the ETB receptor. ABT-546 hydrochloride effectively inhibits ET-1 (HY-P0202)-induced phosphoinositide hydrolysis (IC50 = 0.59 nM) and arachidonic acid release (IC50 = 3.03 nM), and antagonizes ET-1-induced contraction in isolated vascular rings. ABT-546 hydrochloride crosses the placental barrier but shows extremely low fetal exposure, with a favorable safety profile. ABT-546 hydrochloride inhibits ET-1-induced pressor response and downregulates the NLRP3/ROS/GSDMD-mediated pyroptosis pathway. ABT-546 hydrochloride can be used for research on abdominal aortic aneurysm.
-
NLRP3 ligand 1
0 ImagesCat. No.: HY-186343CAS No.: 3115501-02-2
-
NP3-146
0 ImagesCat. No.: HY-145087CAS No.: 210826-47-4Synonyms: NLRP3-IN-5NP3-146 is a NLRP3 inflammasome inhibitor through locking the NACHT domain of NLRP3. NP3-146 shows potent inhibitory activity against IL-1β release with an IC50 value of 0.171 μM in LPS (HY-D1056)/Nigericin (HY-127019)-stimulated BMDM cells. NP3-146 regulates the levels of cleaved Caspase-1 and cleaved IL-1β in cell supernatants. NP3-146 can be used for the research of inflammatory diseases.
-
NLRP3-IN-89
0 ImagesCat. No.: HY-182794CAS No.: 3056637-93-2NLRP3-IN-89 is a NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. NLRP3-IN-89 inhibits the NLRP3 inflammasome pathway, reduces IL-1β secretion, and exhibits minimal interference with the NF-κB pathway. NLRP3-IN-89 can be used for the research of Parkinson's disease, frontotemporal dementia, multiple system atrophy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, or brain injury.
-
ATP ditromethamine
0 ImagesCat. No.: HY-B2176DCAS No.: 102047-34-7Synonyms: Adenosine 5'-triphosphate ditromethamineATP (Adenosine 5'-triphosphate) ditromethamine is a central component of energy storage and metabolism in vivo. ATP ditromethamine provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP ditromethamine is an important endogenous signaling molecule in immunity and inflammation. ATP ditromethamine can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP ditromethamine has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
-
NLRP3-IN-4
0 ImagesCat. No.: HY-132892CAS No.: 2758595-77-4
-
MBL-1
0 ImagesCat. No.: HY-N6189CAS No.: 1815632-13-3MBL-1 is an orally active anti-inflammatory agent. MBL-1 can be isolated from the fermentation broth of Aspergillus sp. derived from gorgonians. MBL-1 inhibits the activity of the hCOX-2 protein with an IC50 of 5.77 μM. MBL-1 reduces the production of key pro-inflammatory mediators such as NO, ROS, IL-1β and IL-18 by inhibiting the MAPK/NF-κB and NLRP3 signaling pathways. MBL-1 exerts a protective effect against DSS-induced colitis. MBL-1 can be used for the research of ulcerative colitis.
-
NQO2 activator-1
0 ImagesCat. No.: HY-180168CAS No.: 1266401-09-5NQO2 activator-1 (Compound 1d) is a selective NQO2 activator with 20.89% increase of NQO2 activity at 10 μM. NQO2 activator-1 strongly inhibits NLRP3 inflammasome activation. NQO2 activator-1 can be used for the research of inflammation and immunology, such as rheumatoid arthritis.
-
Sebrinoflast
0 ImagesCat. No.: HY-177128CAS No.: 2919854-67-2Sebrinoflast (Compound 5) is a NLRP3 inhibitor with an IC50 ≤1 μM for hNLRP3. Sebrinoflast can be used for inflammatory and cardiovascular diseases including NASH and atherosclerosis and neurological diseases like Alzheimer's disease research.
-
Articaine
0 ImagesCat. No.: HY-B0516ACAS No.: 23964-58-1Synonyms: Hoe-045 free baseArticaine (Hoe-045) is a selective inhibitor of voltage-gated sodium channels (such as rNav1.4, hNav1.7, and rNav1.8), with an IC50 of 15.8 μM for open-state Na+ channels, and IC50 of 40.6 μM and 378 μM for inactivated and resting-state Na+ channels, respectively. Articaine exerts local anesthetic activity by inhibiting Na+ influx to block nerve impulse conduction, and can also inhibit NF-κB activation and NLRP3 inflammasome pathways, exhibiting anti-inflammatory function. Articaine can be used in the study of dental local anesthesia and inflammatory-related diseases (such as acute kidney injury).
-
NLRP3-IN-36
0 ImagesCat. No.: HY-163494CAS No.: 3033732-58-7NLRP3-IN-36 (Compound 111) is an NLRP3 inhibitor (IC50 <1 μM).
-
Chiisanogenin
0 ImagesCat. No.: HY-N20708CAS No.: 89353-99-1Chiisanogenin is an orally active triterpenoid. Chiisanogenin reduces postprandial blood glucose by promoting GLUT4 translocation and glucose uptake via activation of the IRS-1/PI3K/Akt signaling pathway. Chiisanogenin binds to MLKL and inhibits its phosphorylation and oligomerization, maintains lysosomal integrity, restores autophagic flux, and suppresses NLRP3 inflammasome activation and pyroptosis. Chiisanogenin inhibits xanthine oxidase activity and regulates oxidative stress and ion pump activity. Chiisanogenin binds to or inhibits PKA, H+/K+-ATPase and β-glucuronidase. Chiisanogenin possesses multiple pharmacological activities, including broad-spectrum antibacterial activity, anticancer, anti-inflammatory, antirheumatic, renoprotective, cardioprotective and antiarrhythmic effects. Chiisanogenin can be used in research related to type 2 diabetes, rheumatoid arthritis, myocardial injury, hepatocellular carcinoma and ventricular arrhythmia.
